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Examination of parity, age at menarche and at menopause by HER2 status in a large series of breast carcinomas showed a statistically
significant increased-frequency of HER2-positive tumours in lower risk subgroups. The findings suggest a difference in the protective
role of hormone-related risk factors between HER2-positive and -negative tumours.
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Clinical and molecular biology findings have led to the identifica-
tion of tumour overexpressing HER2 (HER2+) as a distinct subset
(comprising 20–25%) of breast carcinomas (Slamon et al, 1989;
Ross and Fletcher, 1998, 1999; Me ´nard et al, 2002). This subgroup
is characterised by a high aggressiveness (Ferrero-Pous et al, 2000)
and responsiveness to chemotherapy (Me ´nard et al, 1999b). Since
HER2-positivity has been associated with hormone independence
due to the absence of expression of hormone receptors and
unresponsiveness to tamoxifen (Pietras et al, 1995; Carlomagno
et al, 1996), we hypothesised that hormonal risk factors may not
influence HER2-positive tumours. If this is the case, the proportion
of HER2-positive tumours as part of all tumours should be higher
in the protected subgroup than in the unprotected ones.
To test this hypothesis, in a large surgical database of breast
carcinomas at the National Cancer Institute of Milan from 1968 to
1979, we analysed the frequency of HER2-positive tumours,
determined by immunohistochemistry, according to parity and
age at menarche and at menopause.
PATIENTS AND METHODS
Two series of consecutive patients treated at the Istituto Nazionale
Tumori in Milan, Italy, for primary breast carcinoma were
considered: first, 1211 patients who underwent surgery in 1968–
1969 and received no further treatment (Rilke et al, 1991) and
second, 717 patients operated in 1978–1979 and who then received
adjuvant chemotherapy (Me ´nard et al, 1999a). The two series were
very similar as concerned age at diagnosis, age at menarche, age at
menopause, percent of premenopausal cases, number of children,
nulliparous cases (Table 1). Only natural menopause was
considered. Immunocytochemical staining was retrospectively
carried out on Bouin-fixed, paraffin-embedded tissue using a
polyclonal antibody against HER2-specific peptide (kindly pro-
vided by DJ Slamon), for the first series and anti-HER2 CB11 (1:10
dilution, Ylem, Avezzano, AQ, Italy) for the second series. Both
antibodies revealed a 23% of HER2-positivity and an overlapping
staining on consecutive slides stained with these two reagents
(Mezzelani et al, 1999).
The proportion of HER2-positive tumours was analysed,
according to parity (1655 cases) and age at menarche (1692 cases)
and at menopause (1050 cases). The subgroup with 0 or 1 child,
and the subgroups of o12 or o45, respectively, for age of
menarche and age of menopause were considered as control group
(OR¼1). The expected proportions (EP) of HER2-positivity
were calculated assuming that HER2-positive tumours are not
affected by hormonal risk factors and using the mean odds
ratios (OR) reported for parity, ages at menarche and meno-
pause (Brinton et al, 1988; Vatten and Kvinnsland, 1992; Kelsey
et al, 1993).
Expected proportions were defined as HER2-positive frequency
of control group divided by mean OR reported in the literature for
the risk group considered. Differences in proportions were
analysed using the w
2 test.
RESULTS
The first step in the analysis considered the effect of parity on
HER2-positive breast cancer risk. The proportion of HER2-
positive tumours was found to vary from 20.9% in the group with
zero or one child, to 23.8% in the group with two or three children,
up to 30.5% for women with more than three children (Table 2).
The significant increase of frequency (P¼0.03, w
2-test) of HER2-
positive tumours, according to the parity, suggests that this factor
protects only the HER2-negative tumours. Accordingly, assuming
protection only for the HER2-negative tumour subset and using
the ORs as described in Patients and Methods for parity, the
expected proportions of HER2-positivity would be of 20.9, 22.0 and
27.9% in the respective groups, that is, quite similar to the
observed frequencies (Table 2).
The two other hormonal risk factors for breast carcinomas
recorded in our database, that is, ages at menarche and
menopause, also appear to have a protective impact only on
HER2-negative tumours. In fact, an increased HER2-positive
tumour proportion was observed with increased age at menarche,
which is associated with decreased risk, and a decrease in HER2-
positivity was observed with increased age at menopause, which is
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ORs and assuming protection only for HER2-negative tumours, the
expected frequencies of HER2-positivity are in the range of the
observed ones (Table 2).
DISCUSSION
Altogether our analyses suggest that the three hormone-related
risk factors analysed seem to protect only HER2-negative tumour
subset. These results may be interpreted also as opposite to a
promoting effect of hormone-related risk factors for the HER2-
positive subgroup. Indeed, some clinical data (Carlomagno et al,
1996) have suggested a detrimental effect of tamoxifen treatment
in patients with HER2-positive tumours.
To date, the majority of risk factors for breast carcinomas
identified are related to hormones. Identification of other risk
factors, specific for the onset of HER2-positive tumours might be
hampered by a clouding effect of HER2-negative tumours, which
represent the great majority of breast carcinomas. Indeed, as long
as HER2-positive tumours, which represent only 25% of cases and
therefore of little weight among all breast carcinomas, are analysed
together with the negative ones, it will be difficult to sort out risk
factors for HER2-positive tumours.
In conclusion, our study suggests that HER2-negative and
-positive tumour subsets are influenced differently by breast
carcinoma hormone-related risk factors. To confirm these data,
a cohort study specifically addressing the role of hormone
risk-factors for breast cancer with respect to HER2 status is
going on.
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